Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clinical infectious diseases Ročník 71; číslo 4; s. e1
Hlavní autoři: Daley, Charles L, Iaccarino, Jonathan M, Lange, Christoph, Cambau, Emmanuelle, Wallace, Jr, Richard J, Andrejak, Claire, Böttger, Erik C, Brozek, Jan, Griffith, David E, Guglielmetti, Lorenzo, Huitt, Gwen A, Knight, Shandra L, Leitman, Philip, Marras, Theodore K, Olivier, Kenneth N, Santin, Miguel, Stout, Jason E, Tortoli, Enrico, van Ingen, Jakko, Wagner, Dirk, Winthrop, Kevin L
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 14.08.2020
Témata:
ISSN:1537-6591, 1537-6591
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Instructional Material/Guideline-3
content type line 23
ISSN:1537-6591
1537-6591
DOI:10.1093/cid/ciaa241